Autotaxin and lipid signaling pathways as anticancer targets

Current Opinion in Investigational Drugs

Volumn 11, Issue 6, 2010, Pages 629-637

  Braddock, Demetrios T ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autotaxin; Glioblastoma; Lysophosphatidic acid; Lysophosphatidic acid receptor; Metastasis; Tumor microenvironment

Indexed keywords

ANTINEOPLASTIC AGENT; AUTOTAXIN; LIPID; LYSOPHOSPHATIDIC ACID;

ANGIOGENESIS; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; GLIOBLASTOMA; HUMAN; MALIGNANT TRANSFORMATION; METASTASIS; NONHUMAN; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; STROMA;

ANIMALS; HUMANS; LYSOPHOSPHOLIPIDS; MOLECULAR TARGETED THERAPY; MULTIENZYME COMPLEXES; NEOPLASMS; PHOSPHODIESTERASE I; PYROPHOSPHATASES; SIGNAL TRANSDUCTION;

EID: 77952945271     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Yang 1. SY, Lee J, Park CG, Kim S, Hong S, Chung HC, Min SK, Han JW, Lee HW, Lee HY: Expression of autotaxin (NPP-2) is closely linked to invasiveness of breast cancer cells. Clin Exp Metastasis (2002) 19(7):603-608.
2. Boucharaba A, Serre CM, Guglielmi J, Bordet JC, Clézardin P, 2. Peyruchaud O: The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc Natl Acad Sci USA (2006) 103(25):9643-9648.
3. Liu S, Umezu-Goto M, Murph M, Lu Y, Liu W, Zhang F, Yu S, 3. Stephens LC, Cui X, Murrow G, Coombes K et al: Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell (2009) 15(6):539-550.
4. Raj GV, Sekula JA, Guo R, Madden JF, Daaka Y: 4. Lysophosphatidic acid promotes survival of androgen-insensitive prostate cancer PC3 cells via activation of NFêB. Prostate (2004) 61(2): 105-113.
5. Daaka Y: G proteins in cancer: The prostate cancer paradigm. Sci STKE (2004) 2004(216):re2.
6. Hoelzinger DB, Mariani L, Weis J, Woyke T, Berens TJ, 6. McDonough WS, Sloan A, Coons SW, Berens ME: Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia (2005) 7(1):7-16.
7. Kishi Y, Okudaira S, Tanaka M, Hama K, Shida D, Kitayama J, 7. Yamori T, Aoki J, Fujimaki T, Arai H: Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid. J Biol Chem (2006) 281(25):17492-17500.
8. Hoelzinger DB, Demuth T, Berens ME: 8. Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment. J Natl Cancer Inst (2007) 99(21):1583-1593.
9. Moolenaar WH, van Meeteren LA, Giepmans BN: 9. The ins and outs of lysophosphatidic acid signaling. Bioessays (2004) 26(8):870-881.
10. Noguchi K, Herr D, Mutoh T, Chun J: 10. Lysophosphatidic acid (LPA) and its receptors. Curr Opin Pharmacol (2009) 9(1):15-23.
11. Ishii S, Noguchi K, Yanagida K: 11. Non-Edg family lysophosphatidic acid (LPA) receptors. Prostaglandins Other Lipid Mediat (2009) 89(3-4):57-65.
12. Teo ST, Yung YC, Herr DR, Chun J: 12. Lysophosphatidic acid in vascular development and disease. IUBMB Life (2009) 61(8): 791-799.
13. Contos JJ, Ishii I, Chun J: 13. Lysophosphatidic acid receptors. Mol Pharmacol (2000) 58(6):1188-1196.
14. Hecht JH, Weiner JA, Post SR, Chun J: 14. Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex. J Cell Biol (1996) 135(4):1071-1083.
15. Goetzl EJ, Dolezalova H, Kong Y, Hu YL, Jaffe RB, Kalli KR, 15. Conover CA: Distinctive expression and functions of the type 4 endothelial differentiation gene-encoded G protein-coupled receptor for lysophosphatidic acid in ovarian cancer. Cancer Res (1999) 59(20):5370-5375.
16. Hama K, Aoki J, Fukaya M, Kishi Y, Sakai T, Suzuki R, Ohta H, 16. Yamori T, Watanabe M, Chun J, Arai H: Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1. J Biol Chem (2004) 279(17):17634-17639.
17. Ye X, Hama K, Contos JJ, Anliker B, Inoue A, Skinner MK, 17. Suzuki H, Amano T, Kennedy G, Arai H, Aoki J et al: LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing. Nature (2005) 435(7038):104-108.
18. Lee Z, Cheng CT, Zhang H, Subler MA, Wu J, Mukherjee A, Windle JJ, Chen CK, Fang X: Role of LPA4/p2y9/GPR23 in negative regulation of cell motility. Mol Biol Cell (2008) 19(12):5435-5445.
19. Lin S, Wang D, Iyer S, Ghaleb AM, Shim H, Yang VW, Chun J, Yun CC: The absence of LPA2 attenuates tumor formation in an experimental model of colitis-associated cancer. Gastroenterology (2009) 136(5):1711-1720.
20. Xu Y, Gaudette DC, Boynton JD, Frankel A, Fang XJ, Sharma A, Hurteau J, Casey G, Goodbody A, Mellors A, Holub BJ et al: Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res (1995) 1(10):1223-1232.
21. Hama K, Bandoh K, Kakehi Y, Aoki J, Arai H: Lysophosphatidic acid (LPA) receptors are activated differentially by biological fluids: Possible role of LPA-binding proteins in activation of LPA receptors. FEBS Lett (2002) 523(1-3):187-192.
22. Murph M, Tanaka T, Pang J, Felix E, Liu S, Trost R, Godwin AK, Newman R, Mills G: Liquid chromatography mass spectrometry for quantifying plasma lysophospholipids: Potential biomarkers for cancer diagnosis. Methods Enzymol 2007) 433:1-25.
23. Shan L, Jaffe K, Li S, Davis L: Quantitative determination of lysophosphatidic acid by LC/ESI/MS/MS employing a reversed phase HPLC column. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 864(1-2):22-28.
24. Tokumura A: Physiological and pathophysiological roles of lysophosphatidic acids produced by secretory lysophospholipase D in body fluids. Biochim Biophys Acta (2002) 1582(1-3):18-25.
25. Tokumura A, Harada K, Fukuzawa K, Tsukatani H: Involvement of lysophospholipase D in the production of lysophosphatidic acid in rat plasma. Biochim Biophys Acta (1986) 875(1):31-38.
26. Tokumura A, Majima E, Kariya Y, Tominaga K, Kogure K, Yasuda K, Fukuzawa K: Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. Biol Chem (2002) 277(42):39436-39442.
27. Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, Yamori T, Mills GB, Inoue K, Aoki J, Arai H: Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol (2002) 158(2):227-233.
28. Stracke ML, Krutzsch HC, Unsworth EJ, Arestad A, Cioce V, Schiffmann E, Liotta LA: Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem (1992) 267(4):2524-2529.
29. Stefan C, Jansen S, Bollen M: NPP-type ectophosphodiesterases: Unity in diversity. Trends Biochem Sci (2005) 30(10):542-550.
30. Sakagami H, Aoki J, Natori Y, Nishikawa K, Kakehi Y, Natori Y, Arai H: Biochemical and molecular characterization of a novel choline-specific glycerophosphodiester phosphodiesterase belonging to the nucleotide pyrophosphatase/ phosphodiesterase family. J Biol Chem (2005) 280(24): 23084-23093.
31. Duan RD, Bergman T, Xu N, Wu J, Cheng Y, Duan J, Nelander S, Palmberg C, Nilsson A: Identification of human intestinal alkaline sphingomyelinase as a novel ecto-enzyme related to the nucleotide phosphodiesterase family. J Biol Chem (2003) 278(40):38528-38536.
32. Lee HY, Murata J, Clair T, Polymeropoulos MH, Torres R, Manrow RE, Liotta LA, Stracke ML: Cloning, chromosomal localization, and tissue expression of autotaxin from human teratocarcinoma cells. Biochem Biophys Res Commun (1996) 218(3):714-719.
33. Kawagoe H, Stracke ML, Nakamura H, Sano K: Expression and transcriptional regulation of the PD-Iá/autotaxin gene in neuroblastoma. Cancer Res (1997) 57(12):2516-2521. (Pubitemid 27255915)
34. Yang Y, Mou L, Liu N, Tsao MS: Autotaxin expression in non-small-cell lung cancer. Am J Respir Cell Mol Biol (1999) 21(2):216-222.
35. Kehlen A, Englert N, Seifert A, Klonisch T, Dralle H, Langner J, Hoang-Vu C: Expression, regulation and function of autotaxin in thyroid carcinomas. Int J Cancer (2004) 109(6):833-838.
36. Mills GB, May C, McGill M, Roifman CM, Mellors A: A putative new growth factor in ascitic fluid from ovarian cancer patients: Identification, characterization, and mechanism of action. Cancer Res (1988) 48(5):1066-1071.
37. Mills GB, May C, Hill M, Campbell S, Shaw P, Marks A: Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells. J Clin Invest (1990) 86(3):851-855.
38. Xiao YJ, Schwartz B, Washington M, Kennedy A, Webster K, Belinson J, Xu Y: Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: Comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids. Anal Biochem (2001) 290(2): 302-313.
39. Singh AD, Sisley K, Xu Y, Li J, Faber P, Plummer SJ, Mudhar HS, Rennie IG, Kessler PM, Casey G, Williams BG et al: Reduced expression of autotaxin predicts survival in uveal melanoma. Br J Ophthalmol (2007) 91(10):1385-1392.
40. Nam SW, Clair T, Campo CK, Lee HY, Liotta LA, Stracke ML: Autotaxin (ATX), a potent tumor mitogen, augments invasive and metastatic potential of Ras-transformed cells. Oncogene (2000) 19(2):241-247.
41. Taghavi P, Verhoeven E, Jacobs JJL, Lambooij JP, Stortelers C, Tanger E, Moolenaar WH, van Lohuizen M: In vitro genetic screen identifies a cooperative role for LPA signaling and c-Myc in cell transformation. Oncogene (2008) 27(54):1-11
42. Holland EC: Glioblastoma multiforme: The terminator. Proc Natl Acad Sci USA (2000) 97(12):6242-6244.
43. Hoelzinger DB, Nakada M, Demuth T, Rosensteel T, Reavie LB, Berens ME: Autotaxin: A secreted autocrine/paracrine factor that promotes glioma invasion. J Neurooncol (2008) 86(3): 297-309.
44. Manning TJ Jr, Rosenfeld SS, Sontheimer H: Lysophosphatidic acid stimulates actomyosin contraction in astrocytes. J Neurosci Res (1998) 53(3):343-352.
45. Fukushima N, Weiner JA, Chun J: Lysophosphatidic acid (LPA) is a novel extracellular regulator of cortical neuroblast morphology. Dev Biol (2000) 228(1):6-18.
46. Fox MA, Colello RJ, Macklin WB, Fuss B: Phosphodiesterase- Iá/autotaxin: A counteradhesive protein expressed by oligodendrocytes during onset of myelination. Mol Cell Neurosci (2003) 23(3):507-519.
47. Tanaka M, Okudaira S, Kishi Y, Ohkawa R, Iseki S, Ota M, Noji S, atomi Y, Aoki J, Arai H: Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J Biol Chem (2006) 281(35):25822-25830.
48. Nam SW, Clair T, Kim YS, McMarlin A, Schiffmann E, Liotta LA, Stracke ML: Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor. Cancer Res (2001) 61(18):6938-6944.
49. Guo R, Kasbohm EA, Arora P, Sample CJ, Baban B, Sud N, Sivashanmugam P, Moniri NH, Daaka Y: Expression and function of lysophosphatidic acid LPA1 receptor in prostate cancer cells. Endocrinology (2006) 147(10):4883-4892.
50. Kue PF, Taub JS, Harrington LB, Polakiewicz RD, Ullrich A, Daaka Y: Lysophosphatidic acid-regulated mitogenic ERK signaling in androgen-insensitive prostate cancer PC-3 cells. Int J Cancer 2002) 102(6):572-579.
51. Bookout AL, Finney AE, Guo R, Peppel K, Koch WJ, Daaka Y: Targeting Gâã signaling to inhibit prostate tumor formation and growth. J Biol Chem (2003) 278(39):37569-37573.
52. Kue PF, Daaka Y: Essential role for G proteins in prostate cancer cell growth and signaling. J Urol (2000) 164(6):2162-2167.
53. Guo C, Luttrell LM, Price DT: Mitogenic signaling in androgen sensitive and insensitive prostate cancer cell lines. J Urol (2000) 163(3):1027-1032.
54. Daaka Y: Mitogenic action of LPA in prostate. Biochim Biophys Acta (2002) 1582(1-3):265-269.
55. Price DT, Della Rocca G, Guo C, Ballo MS, Schwinn DA, Luttrell LM: Activation of extracellular signal-regulated kinase in human prostate cancer. J Urol (1999) 162(4):1537-1542.
56. van Meeteren LA, Ruurs P, Christodoulou E, Goding JW, Takakusa H, Kikuchi K, Perrakis A, Nagano T, Moolenaar WH: Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate. J Biol Chem (2005) 280(22):21155-21161.
57. Durgam GG, Virag T, Walker MD, Tsukahara R, Yasuda S, Liliom K, van Meeteren LA, Moolenaar WH, Wilke N, Siess W, Tigyi G et al: Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARã, and inhibitors of autotaxin. J Med Chem (2005) 48(15):4919-4930.
58. Baker DL, Fujiwara Y, Pigg KR, Tsukahara R, Kobayashi S, Murofushi H, Uchiyama A, Murakami-Murofushi K, Koh E, Bandle RW, Byun HS et al: Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis. J Biol Chem (2006) 281(32): 22786-22793.
59. Cui P, Tomsig JL, McCalmont WF, Lee S, Becker CJ, Lynch KR, Macdonald TL: Synthesis and biological evaluation of phosphonate derivatives as autotaxin (ATX) inhibitors. Bioorg Med Chem Lett (2007) 17(6):1634-1640.
60. Cui P, McCalmont WF, Tomsig JL, Lynch KR, Macdonald TL: á- and substituted phosphonate analogs of LPA as autotaxin inhibitors. Bioorg Med Chem (2008) 16(5):2212-2225.
61. North EJ, Osborne DA, Bridson PK, Baker DL, Parrill AL: Autotaxin structure-activity relationships revealed through lysophosphatidylcholine analogs. Bioorg Med Chem (2009) 17(9):3433-3442.
62. Parrill AL, Echols U, Nguyen T, Pham TC, Hoeglund A, Baker DL: Virtual screening approaches for the identification of non-lipid autotaxin inhibitors. Bioorg Med Chem (2008) 16(4):1784-1795.
63. Saunders LP, Ouellette A, Bandle R, Chang WC, Zhou H, Misra RN, De La Cruz EM, Braddock DT: Identification of smallmolecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion. Mol Cancer Ther (2008) 7(10):3352-3362.
64. van Meeteren LA, Ruurs P, Stortelers C, Bouwman P, van Rooijen MA, Pradère JP, Pettit TR, Wakelam MJ, Saulnier-Blache JS, Mummery CL, Moolenaar WH et al: Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol (2006) 26(13):5015-5022.
65. Rivera-Lopez CM, Tucker AL, Lynch KR: Lysophosphatidic acid (LPA) and angiogenesis. Angiogenesis (2008) 11(3):301-310.
66. LaMontagne K, Littlewood-Evans A, Schnell C, O'Reilly T, Wyder L, Sanchez T, Probst B, Butler J, Wood A, Liau G, Billy E et al: Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res (2006) 66(1):221-231.
67. Ho JW, Man K, Sun CK, Lee TK, Poon RT, Fan ST: Effects of a novel immunomodulating agent, FTY720, on tumor growth and angiogenesis in hepatocellular carcinoma. Mol Cancer Ther (2005) 4(9):1430-1438.
68. van Meeteren LA, Brinkmann V, Saulnier-Blache JS, Lynch KR, Moolenaar WH: Anticancer activity of FTY720: Phosphorylated FTY720 inhibits autotaxin, a metastasis-enhancing and angiogenic lysophospholipase D. Cancer Lett (2008) 266(2): 203-208.
69. Zhang H, Xu X, Gajewiak J, Tsukahara R, Fujiwara Y, Liu J, Fells JI, Perygin D, Parrill AL, Tigyi G, Prestwich GD: Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Res (2009) 69(13): 5441-5449.
70. Xu X, Prestwich GD: Inhibition of tumor growth and angiogenesis by a lysophosphatidic acid antagonist in an engineered three-dimensional lung cancer xenograft model. Cancer (2010) 116(7):1739-1750.